XML Sitemap

This is a XML Sitemap which is supposed to be processed by search engines which follow the XML Sitemap standard like Ask.com, Bing, Google and Yahoo.
It was generated using the WordPress content management system and the Google Sitemap Generator Plugin by Arne Brachhold.
You can find more information about XML sitemaps on sitemaps.org and Google's list of sitemap programs.

URLPriorityChange frequencyLast modified (GMT)
https://www.socratec-pharma.de/presentations/how-to-realise-patch-adhesion-studies60%Monthly2015-08-13 09:42
https://www.socratec-pharma.de/presentations/patch-development-with-new-drugs-versus-generic-development--principles-and-methods60%Monthly2015-08-13 09:42
https://www.socratec-pharma.de/presentations/mr-dosage-forms-with-special-release-characteristics60%Monthly2015-08-13 09:42
https://www.socratec-pharma.de/presentations/food-effect-studies-with-mr-products--when-and-how60%Monthly2015-08-13 09:42
https://www.socratec-pharma.de/presentations/pk-characteristics-and-statistical-evaluation-of-be-studies-how-to-handle-the-newly-introduced-endpoints-and-how-to-apply-adaptive-designs60%Monthly2015-08-13 09:42
https://www.socratec-pharma.de/presentations/mr-products-developed-as-line-extension-of-already-approved-ir-formulations60%Monthly2015-08-13 09:42
https://www.socratec-pharma.de/presentations/gcp-and-gmp-inspections-in-phase-i-what-can-be-learned60%Monthly2015-08-13 09:42
https://www.socratec-pharma.de/presentations/bioequivalence-trials-design-development-and-realization-practical-examples-specific-aspects-besides-the-classical-standard-design60%Monthly2015-08-13 09:42
https://www.socratec-pharma.de/presentations/the-basics-of-human-pharmacology-gcp--glp--focus-on-method-validation-bioanalytics-sample-collection-sample-preparation-quality-assurance-procedures60%Monthly2015-08-13 09:42
https://www.socratec-pharma.de/presentations/reference-product-clinical-rationale-of-smpc-recommendations-for-administration60%Monthly2015-08-13 09:42
https://www.socratec-pharma.de/presentations/bcs-based-biowaiver-for-class-iii-drugs60%Monthly2015-08-13 09:42
https://www.socratec-pharma.de/presentations/introductory-session--why-a-global-bioequivalence-harmonisation-initiative-now60%Monthly2015-08-13 09:42
https://www.socratec-pharma.de/presentations/aut-idem--wie-gleich-sind-generika60%Monthly2015-08-13 09:42
https://www.socratec-pharma.de/presentations/oncological-drugs-early-development-from-pre-clinics-to-phase-ii60%Monthly2015-08-13 09:42
https://www.socratec-pharma.de/presentations/trial-medication-drug-substance-product-route-of-administration-formulations-drug-food-interaction-specific-aspects-of-preparation-administration-storage-in-phase-i-drug-accountability-test-refer60%Monthly2018-09-02 21:27
https://www.socratec-pharma.de/presentations/key-note-bedeutung-der-clinical-trial-regulation-fuer-die-humanpharmakologische-forschung-in-deutschland60%Monthly2015-08-13 09:42
https://www.socratec-pharma.de/presentations/ema-consideration-for-locally-acting-drugs-in-the-gi-tract60%Monthly2015-08-13 09:42
https://www.socratec-pharma.de/presentations/example-sulfasalazine--combination-of-bioequivalence--localisation-study60%Monthly2015-08-13 09:42
https://www.socratec-pharma.de/presentations/investigating-individual-plasma-profiles-conclusion-on-comparability-of-product-performance-and-site-of-drug-deliveryabsorption-from-the-gi-tract60%Monthly2015-08-13 09:42
https://www.socratec-pharma.de/presentations/how-to-increase-drugability-by-use-of-specific-formulations--locally-acting-locally-applied60%Monthly2015-08-13 09:42
https://www.socratec-pharma.de/presentations/how-relevant-are-drug-food-interactions60%Monthly2015-08-13 09:42
https://www.socratec-pharma.de/presentations/pkpd-trials-in-drug-device-combinations-inhaled-glucocorticoids-as-example-for-complex-early-clinical-development-plans60%Monthly2015-08-13 09:42
https://www.socratec-pharma.de/presentations/gcp--glp--focus-on-method-validation-bioanalytics-sample-collection-sample-preparation-quality-assurance-procedures60%Monthly2015-08-13 09:42
https://www.socratec-pharma.de/presentations/the-basics-of-human-pharmacology-trial-medication60%Monthly2015-08-13 09:42
https://www.socratec-pharma.de/presentations/wann-ist-der-gesunde-proband-gesund-genug-fuer-die-klinische-pruefung60%Monthly2015-08-13 09:42
https://www.socratec-pharma.de/presentations/revised-european-guideline-on-pharmacokinetic-and-clinical-evaluation-of-modified-release-dosage-forms60%Monthly2015-08-13 09:42
https://www.socratec-pharma.de/presentations/development-of-formulations-with-added-value60%Monthly2015-08-13 09:42
https://www.socratec-pharma.de/presentations/protocol-development-definition-of-inex-criteria-and-clinical-conduct-of-babe-studies-in-patients60%Monthly2016-11-22 10:37
https://www.socratec-pharma.de/presentations/pharmacokinetic-and-bioanalytical-issues-in-patient-studies60%Monthly2015-08-13 09:42
https://www.socratec-pharma.de/presentations/validation-of-pharmacodynamic-methods-and-endpoints60%Monthly2015-08-13 09:42
https://www.socratec-pharma.de/presentations/implants-and-vaginally-administered-devices60%Monthly2015-08-13 09:42
https://www.socratec-pharma.de/presentations/how-to-substitute-efficacysafety-studies-by-pd-analysis-in-locally-appliedlocally-acting-drugs60%Monthly2015-08-13 09:42
https://www.socratec-pharma.de/presentations/biosimilars-concepts-for-therapeutic-antibodies60%Monthly2015-08-13 09:42
https://www.socratec-pharma.de/presentations/babe-in-paediatric-population--what-may-be-extrapolated-from-findings-in-adults60%Monthly2015-08-13 09:42
https://www.socratec-pharma.de/presentations/phase-i-studies-with-newly-developed-liposomal-formulations-safety-and-efficacy-issues60%Monthly2015-08-13 09:42
https://www.socratec-pharma.de/presentations/liposomal-iv-preparations-rationale-for-development--characterization60%Monthly2015-08-13 09:42
https://www.socratec-pharma.de/presentations/chmp-guideline-on-bioanalytical-method-validation60%Monthly2015-08-13 09:42
https://www.socratec-pharma.de/presentations/opioid-retardarzneimittel-warum-ist-die-galenik-so-bedeutsam60%Monthly2015-08-13 09:42
https://www.socratec-pharma.de/presentations/be-and-adme-studies-in-oncological-patient-populations60%Monthly2015-08-13 09:42
https://www.socratec-pharma.de/presentations/generating-meaningful-clinical-information-impact-ofon-early-formulation-development60%Monthly2015-08-13 09:42
https://www.socratec-pharma.de/presentations/pharmacokinetics-meets-biopharmaceutics-rationale-for-chrono-adjusted-pharmacotherapy60%Monthly2015-08-13 09:42
https://www.socratec-pharma.de/presentations/generische-substitution-ist-ein-austausch-mit-therapeutischen-risiken-verbunden60%Monthly2015-08-13 09:42
https://www.socratec-pharma.de/presentations/verhalten-von-retardarzneimitteln-im-magen-darm-trakt-bedeutung--interpretation-von-food-effects60%Monthly2015-08-13 09:42
https://www.socratec-pharma.de/presentations/anlage-und-durchfuehrung-von-bioverfuegbarkeits--und-bioaequivalenzstudien60%Monthly2015-08-13 09:42
https://www.socratec-pharma.de/presentations/biopharmazeutische-konzepte-koennen-medikamentoese-therapie-optimieren60%Monthly2015-08-13 09:42
https://www.socratec-pharma.de/presentations/revised-european-be-guideline-major-changes-new-challenges60%Monthly2015-08-13 09:42
https://www.socratec-pharma.de/presentations/draft-reflection-paper-on-guidance-for-laboratories-analysing-or-evaluating-clinical-trial-samples60%Monthly2015-08-13 09:42
https://www.socratec-pharma.de/presentations/chmp-guideline-on-bioanalytical-method-validation60%Monthly2015-08-13 09:42
https://www.socratec-pharma.de/presentations/kostensenkung-durch-generische-substitution-und-rabattvertraege-muss-der-patient-die-zeche-zahlen60%Monthly2015-08-13 09:42
https://www.socratec-pharma.de/presentations/medikamentoese-schmerztherapie-warum-die-galenik-so-entscheidend-ist60%Monthly2015-08-13 09:42
https://www.socratec-pharma.de/presentations/einfluss-der-physiologie-des-magen-darm-traktes-auf-die-resorption-von-arzneimitteln60%Monthly2015-08-13 09:42
https://www.socratec-pharma.de/presentations/biopharmazie-einfluss-der-arzneimittelform-auf-die-arzneimittelwirkung60%Monthly2015-08-13 09:42
https://www.socratec-pharma.de/presentations/european-perspective-for-fixed-dose-combinations60%Monthly2015-08-13 09:42
https://www.socratec-pharma.de/presentations/be-studies-in-patient-populations--new-challenges-and-future-trends60%Monthly2015-08-13 09:42
https://www.socratec-pharma.de/presentations/dpp-4-inhibitoren-ein-vergleich-aus-pharmakologischer-sicht60%Monthly2015-08-13 09:42
https://www.socratec-pharma.de/presentations/enhanced-pdclinical-outcome-through-optimizing-drug-delivery60%Monthly2015-08-13 09:41
https://www.socratec-pharma.de/presentations/kostensenkung-durch-generische-substitution-und-rabattvertraege-muss-der-patient-die-zeche-zahlen60%Monthly2015-08-13 09:41
https://www.socratec-pharma.de/presentations/clinical-trials-for-line-extension-added-value-generics-and-novel-drug-delivery-systems60%Monthly2015-08-13 09:41
https://www.socratec-pharma.de/presentations/bioequivalence-andor-therapeutic-equivalence-for-generics--not-by-choice-but-must60%Monthly2015-08-13 09:41
https://www.socratec-pharma.de/presentations/example-for-an-early-drug-device-development-plan60%Monthly2015-08-13 09:41
https://www.socratec-pharma.de/presentations/food-effect-studies-influence-of-population-characteristics-and-standardisation-of-clinical-procresses60%Monthly2015-08-13 09:41
https://www.socratec-pharma.de/presentations/bioaequivalenzstudien-mit-speziellen-arzneimitteln-fdc-odt-etc60%Monthly2016-11-22 11:38
https://www.socratec-pharma.de/presentations/pruefpraeparate-auswahl-und-charakterisierung-qualitaetsanforderungen-bevorzugte-wirkstaerke-bracketing-etc60%Monthly2015-08-13 09:41
https://www.socratec-pharma.de/presentations/selection-of-reference-product-in-bioequivalence-studies-for-submission-to-multiple-jurisdictions60%Monthly2015-08-13 09:41
https://www.socratec-pharma.de/presentations/drug-delivery-technologies-to-optimize-the-clinical-application-of-drugs60%Monthly2016-11-22 10:38
https://www.socratec-pharma.de/presentations/major-differences-beetwen-ema-fda-and-who-guidances-in-be-and-bcs60%Monthly2015-08-13 09:41
https://www.socratec-pharma.de/presentations/emas-bioanalytical-guidance60%Monthly2015-08-13 09:41
https://www.socratec-pharma.de/presentations/bioequivalence-regulations-for-modified-release-products-necessity-of-single-dose-fasted-food-effect--multiple-dose-studies60%Monthly2015-08-13 09:41
https://www.socratec-pharma.de/presentations/pharmako-therapeutische-schmerzkontrolle-besonderheiten-unterschiedlicher-applikationswege60%Monthly2015-08-13 09:41
https://www.socratec-pharma.de/presentations/lueckenlose-schmerzkontrolle-in-der-opiat-therapie-behandlungslonzept-und-erwartungen-an-der-arzneiform60%Monthly2015-08-13 09:41
https://www.socratec-pharma.de/presentations/pharmazeutische-bedenken-und-rabattvertraege-aut-idem-lichte-der-guten-substitutionspraxis60%Monthly2015-08-13 09:41
https://www.socratec-pharma.de/presentations/modern-strategies-for-the-development-of-gerneric-drugs-highly-variable-drugs-mechanisms-for-high-variability-and-resolutions-to-overcome-the-differences60%Monthly2015-08-13 09:41
https://www.socratec-pharma.de/presentations/modern-strategies-for-the-development-of-gerneric-drugs-locally-acting--locally-applied-drug-products-a-playing-field-for-human-pharmacologists60%Monthly2015-08-13 09:41
https://www.socratec-pharma.de/presentations/babe--important-link-between-drug-quality-and-efficacysafety60%Monthly2015-08-13 09:41
https://www.socratec-pharma.de/presentations/before-or-after-a-meal-impact-of-administration-conditions-on-clinical-efficacy60%Monthly2015-08-13 09:41
https://www.socratec-pharma.de/presentations/different-salts-of-a-pro-drug-more-restrictive-be-requirements60%Monthly2015-08-13 09:41
https://www.socratec-pharma.de/presentations/food-effect-studies-towards-science-driven-regulations60%Monthly2015-08-13 09:41
https://www.socratec-pharma.de/presentations/drugs-mainly-taken-by-the-elderly-be-testing-in-the-target-population60%Monthly2015-08-13 09:41
https://www.socratec-pharma.de/presentations/the-class-war-the-problem-of-combining-bcs-class-i-and-iii-in-biowaivers60%Monthly2015-08-13 09:41
https://www.socratec-pharma.de/presentations/be-of-modified-release-products-difficult-eytrapolation-from-in-vitro60%Monthly2015-08-13 09:41
https://www.socratec-pharma.de/presentations/bioavailability-bioequivalence-development-of-international-regualtory-requirements60%Monthly2015-08-13 09:41
https://www.socratec-pharma.de/presentations/bcs-based-biowaivers60%Monthly2015-08-13 09:41
https://www.socratec-pharma.de/presentations/use-of-bcs-in-product-development-background--concept--perspective60%Monthly2015-08-13 09:41
https://www.socratec-pharma.de/presentations/therapeutische-optimierung-durch-innovative-arzneiformen60%Monthly2015-08-13 09:41
https://www.socratec-pharma.de/presentations/vom-konzept-zur-praxis--klinische-pruefung-unter-nutzung-von-surrogatparametern60%Monthly2015-08-13 09:41
https://www.socratec-pharma.de/presentations/phase-i-studien-wie-werden-die-anforderungen-und-schnittstellen-effizient-vereinbart60%Monthly2015-08-13 09:41
https://www.socratec-pharma.de/presentations/babe-studies-with-mr-products-a-european-perspective60%Monthly2015-08-13 09:41
https://www.socratec-pharma.de/presentations/survey-of-international-bioequivalence-requirements60%Monthly2015-08-13 09:41
https://www.socratec-pharma.de/presentations/bioequivalence-regulations-survey-of-international-requirements60%Monthly2015-08-13 09:41
https://www.socratec-pharma.de/presentations/seminar-bioavailabilitybioequivalence-and-in-vitro-dissolution60%Monthly2015-08-13 09:41
https://www.socratec-pharma.de/presentations/aut-idem-substitution-sind-analgetika-zur-therapie-chronischer-schmerzen-einfach-austauschbar60%Monthly2015-08-13 09:41
https://www.socratec-pharma.de/presentations/highly-variable-drugs-how-to-solve-significant-problems-assessing-bioequivalence60%Monthly2015-08-13 09:41
https://www.socratec-pharma.de/presentations/bioequivalence-regulations--bar-or-driving-force-for-progress-in-science-and-technology60%Monthly2015-08-13 09:41
https://www.socratec-pharma.de/presentations/biosimilars--how-similar-is-similar60%Monthly2015-08-13 09:41
https://www.socratec-pharma.de/presentations/schlafstoerung-bei-der-behandlung-chronischer-schmerzzustaende--besserung-durch-optimale-galenik60%Monthly2015-08-13 09:41
https://www.socratec-pharma.de/presentations/qualitaet-und-innovation-als-mehrwertsteuer--chancen-fuer-added-value-generics60%Monthly2015-08-13 09:41
https://www.socratec-pharma.de/presentations/therapeutische-optimierung-durch-innovative-arzneiformen60%Monthly2015-08-13 09:41
https://www.socratec-pharma.de/presentations/charakterisierung-der-in-vitro-freisetzung-fester-oraler-darreichungsformen60%Monthly2015-08-13 09:41
https://www.socratec-pharma.de/presentations/revision-of-cpmp-note-for-guidance-on-babe-regulatory-and-scientific-rationale60%Monthly2015-08-13 09:41
https://www.socratec-pharma.de/presentations/orodispersible-tablets-necessity-to-investigate-fed-and-fasted-intake60%Monthly2015-08-13 09:41
https://www.socratec-pharma.de/presentations/bcs-based-biowaiver-extension-to-class-iii-drugs60%Monthly2015-08-13 09:41
https://www.socratec-pharma.de/presentations/bedeutung-gleichmaessiger-plasmaprofile-in-der-schmerztherapie60%Monthly2015-08-13 09:41
https://www.socratec-pharma.de/presentations/development-of-super-generic-new-chances-for-old-drugs60%Monthly2015-08-13 09:41
https://www.socratec-pharma.de/presentations/bioverfuegbarkeit-und-rabattvertraege--ein-problematisches-wechselspiel60%Monthly2015-08-13 09:41
https://www.socratec-pharma.de/presentations/physiologische-und-pharmakologische-grundlagen-inkretinbasierter-therapieansaetze60%Monthly2015-08-13 09:41
https://www.socratec-pharma.de/presentations/impact-of-product-quality-on-the-treatment-with-alpha-lipoic-acid60%Monthly2015-08-13 09:41
https://www.socratec-pharma.de/presentations/austauschbarkeit-von-antiepileptika--pro-und-contra60%Monthly2015-08-13 09:41
https://www.socratec-pharma.de/presentations/babe-studies-with-modified-release-products--a-european-perspective60%Monthly2015-08-13 09:41
https://www.socratec-pharma.de/presentations/revision-of-the-cpmp-note-for-guidance-on-babe-impact-on-the-development-of-generic-medicinal-products60%Monthly2015-08-13 09:41
https://www.socratec-pharma.de/presentations/food-effect-studies-towards-science-driven-regulations60%Monthly2015-08-13 09:41
https://www.socratec-pharma.de/presentations/new-therapeutic-entities-novel-biopharmaceutical-concepts-for-improved-clinical-efficacy60%Monthly2015-08-13 09:41
https://www.socratec-pharma.de/presentations/successfully-performing-bioavailabilitybioequivalence-studies-for-modified-release-products60%Monthly2015-08-13 09:41
https://www.socratec-pharma.de/presentations/antihypertensive-therapie-warum-die-arztneimittelqualitaet-hier-besonders-wichtig-ist60%Monthly2015-08-13 09:41
https://www.socratec-pharma.de/presentations/pharmakologische-bewertung-oraler-antidiabetika60%Monthly2015-08-13 09:41
https://www.socratec-pharma.de/presentations/therapie-chronischer-schmerzzustaende-kriterien-fuer-optimale-opiodarzneimittel60%Monthly2015-08-13 09:41
https://www.socratec-pharma.de/presentations/iontophorese-und-postoperative-schmerztherapie60%Monthly2015-08-13 09:40
https://www.socratec-pharma.de/presentations/site-dependent-drug-absorption-and-impact-on-babe-assessment60%Monthly2016-11-22 10:40
https://www.socratec-pharma.de/presentations/assessment-of-intestinal-and-hepatic-first-pass-necessity-to-measure-metabolites60%Monthly2015-08-13 09:40
https://www.socratec-pharma.de/presentations/optimising-gi-absorption-of-modified-release-products60%Monthly2015-08-13 09:40
https://www.socratec-pharma.de/presentations/therapeutische-optimierung-durch-galenische-modifizierung60%Monthly2015-08-13 09:40
https://www.socratec-pharma.de/presentations/the-need-for-and-approaches-to-a-european-healthy-volunteer-database60%Monthly2016-11-22 10:43
https://www.socratec-pharma.de/presentations/life-cycle-management-new-chances-for-old-drugs60%Monthly2015-08-13 09:40
https://www.socratec-pharma.de/presentations/optimierte-arzneiformen-zur-verbesserung-der-pharmakotherapie-beim-alten-menschen60%Monthly2015-08-13 09:40
https://www.socratec-pharma.de/presentations/gastro-intestinal-transit-of-solid-oral-dosage-forms-imaging-studies-using-magnetic-marker-monitoring-technique60%Monthly2015-08-13 09:40
https://www.socratec-pharma.de/presentations/hightech-in-der-schmerztherapie-therapeutische-optimierung-durch-osmotisch-gesteuerte-retardform60%Monthly2015-08-13 09:40
https://www.socratec-pharma.de/presentations/bioavailability-and-bioequivalence-studies-for-modified-release-products60%Monthly2015-08-13 09:40
https://www.socratec-pharma.de/presentations/modified-release-oxcarbazepine-challenges-and-successful-development60%Monthly2015-08-13 09:40
https://www.socratec-pharma.de/presentations/leitsubstanzen-in-der-arzneitherapie-konflikt-zwischen-wirtschaftlichkeit-und-innovationen60%Monthly2015-08-13 09:40
https://www.socratec-pharma.de/presentations/innovation-oder-scheininnovation-welche-rolle-spielt-die-arzneiform60%Monthly2015-08-13 09:40
https://www.socratec-pharma.de/presentations/schlucken-oder-kleben--biopharmazeutische-antworten-auf-eine-therapierelevante-frage60%Monthly2015-08-13 09:40
https://www.socratec-pharma.de/presentations/neue-konzepte-fuer-die-optimierung-oraler-antidiabetika60%Monthly2015-08-13 09:40
https://www.socratec-pharma.de/presentations/biosimilars--qualitaet-und-sicherheit-einer-besonderen-arzneimittelgruppe60%Monthly2015-08-13 09:40
https://www.socratec-pharma.de/presentations/drug-interaction-studies-the-rational-selection-of-drug-interaction-studies60%Monthly2015-08-13 09:40
https://www.socratec-pharma.de/presentations/once-daily-nifedipine-products-are-they-really-interchangeable60%Monthly2015-08-13 09:40
https://www.socratec-pharma.de/presentations/fentanyl-pflaster--eine-therapeutische-bereicherung60%Monthly2015-08-13 09:40
https://www.socratec-pharma.de/presentations/bioavailabilitybioequivalence-practise-and-issues60%Monthly2015-08-13 09:40
https://www.socratec-pharma.de/presentations/single-vs-multiple-dose-studien-standards-und-besonderheiten60%Monthly2015-08-13 09:40
https://www.socratec-pharma.de/presentations/retardarzneiformen-was-tun-bei-nicht-aequivalenz60%Monthly2015-08-13 09:40
https://www.socratec-pharma.de/presentations/retardformen-und-food-effects-von-dose-dumping-und-anderen-unerfreulichen-ueberraschungen60%Monthly2015-08-13 09:40
https://www.socratec-pharma.de/presentations/arzneimittel-konflikt-zwischen-kosten-und-qualitaet60%Monthly2015-08-13 09:40
https://www.socratec-pharma.de/presentations/sicherheit-und-vertraeglichkeit-von-propiverin-bei-patienten-mit-nierenfunktionseinschraenkung60%Monthly2015-08-13 09:40
https://www.socratec-pharma.de/presentations/new-perspectives-for-added-value-generics60%Monthly2015-08-13 09:40
https://www.socratec-pharma.de/presentations/bioverfuegbarkeitbioaequivalenz-und-magen-darm-physiologie-wird-das-konzept-auf-den-kopf-gestellt60%Monthly2015-08-13 09:40
https://www.socratec-pharma.de/presentations/babe--an-important-link-between-drug-quality-and-efficacysafety60%Monthly2015-08-13 09:40
https://www.socratec-pharma.de/presentations/magen-darm-therapeutika-warum-ist-die-arzneiform-so-bedeutsam60%Monthly2015-08-13 09:40
https://www.socratec-pharma.de/presentations/properties-of-special-populations60%Monthly2015-08-13 09:40
https://www.socratec-pharma.de/presentations/innovative-galenik-die-voraussetzung-fuer-eine-optimierte-therapie-des-chronischen-schmerzes60%Monthly2015-08-13 09:40
https://www.socratec-pharma.de/presentations/aktuelle-fragen-zur-bioaequivalenz60%Monthly2015-08-13 09:40
https://www.socratec-pharma.de/presentations/nachweis-der-bioaequivalenz-wann-welche-studienkonzeption60%Monthly2015-08-13 09:40
https://www.socratec-pharma.de/presentations/charakterisierung-der-bioverfuegbarkeitbioaequivalenz-grundkonzept-und-studienansaetze60%Monthly2015-08-13 09:40
https://www.socratec-pharma.de/presentations/anlage-und-durchfuehrung-von-bioaequivalenzstudien60%Monthly2015-08-13 09:40
https://www.socratec-pharma.de/presentations/anlage-und-durchfuehrung-von-bioverfuegbarkeitsuntersuchungen60%Monthly2015-08-13 09:40
https://www.socratec-pharma.de/presentations/designing-and-evaluating-babe-studies-in-the-21st-century60%Monthly2015-08-13 09:40
https://www.socratec-pharma.de/presentations/arzneimittel-fe-heute-wiederentdeckung-der-arzneiform60%Monthly2015-08-13 09:40
https://www.socratec-pharma.de/presentations/therapeutische-optimierung-nicht-denkbar-ohne-klinische-rationale60%Monthly2015-08-13 09:40
https://www.socratec-pharma.de/presentations/proof-of-concept-stellenwert-von-pd-studien-und-surrogatparametern60%Monthly2015-08-13 09:40
https://www.socratec-pharma.de/presentations/neue-arzneimittel-strategien-zur-vermeidung-gefaehrlicher-interaktionen60%Monthly2015-08-13 09:40